Volume 12, Number 4—April 2006
Research
Contrasting Pediatric and Adult Methicillin-resistant Staphylococcus aureus Isolates
Table 2
Antimicrobial drug | Adult outpatient isolates (n = 105) | Pediatric outpatient isolates (n = 115) | p value* |
---|---|---|---|
Ciprofloxacin | 55.2 | 9.6 | <0.001 |
Clindamycin | |||
Resistant† | 37.1 | 6.1 | <0.001 |
D-test positive‡ | 20.4 | 14.8 | 0.39 |
Erythromycin | 91.4 | 88.7 | 0.16 |
Gentamicin | 8.6 | 1.7 | 0.03 |
Rifampin | 1.9 | 0 | 0.23 |
Tetracycline§ | 13.3 | 3.6 | 0.01 |
TMP-SMX¶ | 0 | 0 | NA |
Vancomycin | 0 | 0 | NA |
*p value compares resistance to indicated antimicrobial drugs or positive test result among adult vs. pediatric isolates by χ2 test or Fisher exact test. NA, not applicable.
†Figures in this row represent Vitek testing results for clindamycin.
‡54 (97.1%) and 88 (93.9%) of the adult and pediatric isolates, respectively, that were erythromycin resistant and clindamycin susceptible by Vitek were evaluated by D-testing.
§Tetracycline susceptibility was not tested for 5 pediatric outpatient isolates and 2 adult outpatient isolates.
¶TMP-SMX, trimethoprim-sulfamethoxazole. Only 42 adult and 27 pediatric isolates that were erythromycin resistant and clindamycin susceptible were tested.
Page created: January 24, 2012
Page updated: January 24, 2012
Page reviewed: January 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.